Regeneron has beaten earnings estimates in all four of the last four quarters with an average surprise of 22%, trades at a forward price-to-earnings of 11.4x with 22% analyst upside, and maintains strong net margins of 30% — but faces declining earnings estimates, weak revenue growth, and near-term technical weakness from a death cross, creating a fundamentally sound but momentum-challenged setup.
Thesis pillars
- Strong Margins And Financial Health→Stable
- Perfect Earnings Beat Streak Quality→Stable
- Attractive Valuation Versus Peers↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 4, 2026· older than 90 days
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $957.76, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away).
Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net product sales (31% of revenues) and Sanofi collaboration revenue from Dupixent (41% of revenues). The company has multiple approved products spanning ophthalmology,... Read more
Hold if already holding. Not a fresh buy at $957.76, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
No fresh coverage since Oct 28, 2026
Recent Developments — Regeneron Pharmaceuticals, Inc.
Latest news
- NEWS Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued (NASDAQ:REGN) - Seeking Alpha — Seeking Alpha Oct 28, 2026 neutral
- NEWS Missed Regeneron Pharmaceuticals' Rally? Here Is The Bull Case - Yahoo Finance — Yahoo Finance Oct 28, 2026 negative
- NEWS Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga — Benzinga Oct 27, 2026 neutral
- NEWS REGN Maintained by TD Cowen -- Price Target Raised to $980 - GuruFocus — GuruFocus Oct 21, 2026 positive
- NEWS Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen - MarketBeat — MarketBeat Oct 21, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-18T11:27:30Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductEYLEA HD and EYLEA31%10-K Item 1A: 'our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31%...of our total revenues'
- MEDIUMcounterpartySanofi41%10-K Item 1A: 'Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 41%...of our total revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $957.76, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $891.73 reached (−6.9%), stop $890.72 (−7.5%), A.R:R -0.5:1. Score 6.8/10, moderate confidence.
Analyst target $891.73 reached (−6.9% from $957.76); no take-profit level is published. Analyst target $891.73 reached (−6.9%), stop $890.72 (−7.5%), A.R:R -0.5:1. Stop-loss: $890.72.
Analyst target reached - limited upside remaining; Near 52-week high (3.4% away).
Regeneron Pharmaceuticals, Inc. trades at a P/E of 21.1 (forward 13.5). TrendMatrix value score: 5.8/10. Verdict: Hold.
36 analysts rate REGN, with a consensus score of 3.9/5. 27 analysts publish price targets averaging $991.
What does Regeneron Pharmaceuticals, Inc. do?Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net...
Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net product sales (31% of revenues) and Sanofi collaboration revenue from Dupixent (41% of revenues). The company has multiple approved products spanning ophthalmology, immunology, oncology, and rare diseases, partnering with Sanofi and Bayer for select commercialization outside the US.